Marc Beer is the Founding Chairman and Chief Executive Officer of one of the most influential and fastest growing a biotechnology company, Renovia Inc. For the few who don’t know, Renovia creates products for better first-line diagnosis and treatment of rare pelvic conditions, particularly in women. The company is based in Boston.
Mark Beer’s Achievements as the CEO and Founder of Renovia Inc.
Thanks to Marc’s experience and exceptional leadership skills, Renovia has evolved from an unknown pharmaceutical start-up to a robust commercial enterprise serving millions of people from all over the world. Marc’s vast network has also enabled the company to attract high-profile investors including, OSF Ventures, Nova Strategic Investments, Western Technology Investment, Cormorant Asset Management, and Longwood Fund. These investors have invested more than $45 billion in the company.
But that’s not. The visionary was also part of the team that helped create, test, and launches Leva, Renovia’s first product. Leva recently got approval from the Food and Drug Administration (FDA) thanks to Marc’s efforts and dedication. The CEO is also part of the team that is focused on helping Renovia create and deliver products that will improve the diagnosis and treatment of urinary incontinence. Urinary incontinence is a pelvic condition that, according to recent research, affects more than 250 million women around the world. The visionary has also helped bring talented people on board and is helping the company come up with better products and more effective strategies.
Education and Career
Marc is an alumnus of Miami University, where he pursued a BS degree. After completing his undergraduate studies, the talented businessman went to work at Abbott Laboratories, where he served as a marketer and a customer rep. During his stint at Abbott Laboratories, Marc helped the pharmaceutical company come up with cerebral sales and marketing strategies that beat any competition that came its way. He also helped the company expand to new regions. Learn more: https://renoviainc.com/leadership/
A few years later, Marc left Abbott Laboratories and joined Genzyme, where he served as VP of Global Marketing. At Genzyme, he helped create, test, and launch several products, devices, and treatments to fight the rare disease around the world.
In 2000, he founded ViaCell, a biotechnology company that he later sold to PerkinElmer. The exceptional leader also served as a member of the Board of Directors of ERYP. He also serves as Chairman of Good Start Genetics.